Nova Eye Medical Reports Record Revenues for FY25
Key points
- Record revenues of A$28.8m for FY25, up 21% from FY24
- Six consecutive half-years of growth in the USA, with H2FY25 US sales up 25% on pcp
- Q4FY25 sales of A$8.4m, the highest on record
Full summary
Nova Eye Medical Limited (ASX: EYE) has reported a record sales result for the financial year ended 30 June 2025. Group revenue for FY25 reached A$28.8 million (US$18.4 million), up 21% (in constant currency) from FY24. The key drivers of this record performance include US sales of US$14.2 million, up 25% with the iTrack™ Advance device delivering six consecutive half-years of revenue growth. Second half FY25 sales reached A$15.7 million (US$10 million), up 46% on the prior corresponding period (in constant currency) and in line with guidance. Q4FY25 sales of A$8.4 million (US$5.4 million) were the highest on record. The record result underscores the continued adoption of iTrack™ Advance and growing global recognition of Nova Eye's technology. Nova Eye expects revenue growth to continue in FY26.
Guidance
Nova Eye expects revenue growth to continue in FY26.
Summary generated by a large language model. Please interpret with care.